
    
      This is a single arm, phase 2 study of neoadjuvant triplet chemotherapy regimen of
      oxaliplatin, irinotecan combined with 5-fluorouraci/leucovorin or S-1 or capecitabine in
      patients with resectable colorectal cancer.Fifty patients will be enrolled in this trial. The
      primary objective of this study is to determine the 3-year disease-free survival of the
      patients.
    
  